Table 4.
Results of traditional meta-analysis and meta-regression analyses of proportion of INR measurements in range
| |
|
Proportion of INR measurements in range |
||
|---|---|---|---|---|
| Study-level factors | No. (%) | Unadjusted pooled mean upon subgroup analysis, % (95% CI) | Adjusted difference, % (95% CI) | p-v alue |
| All study groups |
24 (100) |
56 (53 to 59) |
NA |
NA |
| Study setting |
|
|
|
|
| AC Clinic |
5 (20.8) |
60 (58 to 62) |
6.9 (−0.02 to 15.2) |
0.13 |
| RCT |
5 (20.8) |
61 (54 to 68) |
5.6 (−0.06 to 17.0) |
0.36 |
| Community |
14 (58.3) |
54 (50 to 57) |
Referent |
|
| Study year |
|
|
|
|
| 1990-2000 |
6 (25.0) |
54 (46 to 64) |
3.3 (−25.3 to 31.9) |
0.82 |
| 2001-2007 |
13 (54.2) |
56 (54 to 59) |
−2.8 (−14.8 to 9.2) |
0.65 |
| 2008-2013 |
5 (20.8) |
56 (51 to 62) |
Referent |
|
| Self-management |
|
|
|
|
| No |
22 (91.7) |
55 (43 to 57) |
−9.3 (−32.4 to 13.8) |
0.45 |
| Yes |
2 (8.3) |
69 (67 to 72) |
Referent |
|
| Geographic region |
|
|
|
|
| Europe/UK |
13 (54.2) |
57 (54 to 60) |
−1.7 (−10.7 to 7.3) |
0.71 |
| Asia |
2 (8.3) |
56 (48 to 66) |
−8.8 (−26.4 to 8.8) |
0.32 |
| Other |
0 (0) |
NA |
NA |
NA |
| Multinational |
0 (0) |
NA |
NA |
NA |
| North America |
9 (37.5) |
54 (48 to 62) |
Referent |
|
| VKA experience |
|
|
|
|
| NR/Mixed |
5 (20.8) |
51 (41 to 63) |
−5.7 (−34.7 to 23.3) |
0.83 |
| No |
3 (12.5) |
63 (55 to 73) |
7.9 (−15.2 to 31.0) |
0.65 |
| Yes |
17 (70.8) |
56 (54 to 59) |
Referent |
|
| Duration of VKA treatment |
|
|
|
|
| ≥1 year |
17 (70.8) |
57 (54 to 60) |
9.1 (−0.5 to 18.7) |
0.09 |
| <1 year | 7 (29.2) | 53 (44 to 65) | Referent | |
AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = not reported; RCT = randomized controlled trial; UK = United Kingdom; VKA = Vitamin K Antagonists.